"Company","Parent Company","Penalty Amount","Subtraction From Penalty","Penalty Amount Adjusted For Eliminating Multiple Counting","Penalty Year","Penalty Date","Offense Group","Primary Offense","Secondary Offense","Description","Level of Government","Action Type","Agency","Civil/Criminal","Prosecution Agreement","Court","Case ID","Private Litigation Case Title","Lawsuit Resolution","Facility State","City","Address","Zip","NAICS Code","NAICS Translation","HQ Country of Parent","HQ State of Parent","Ownership Structure","Parent Company Stock Ticker","Major Industry of Parent","Specific Industry of Parent","Info Source","Notes"
"Insys Therapeutics","Insys Therapeutics","$225,000,000","$0","$225,000,000","2019","20190605","government-contracting-related offenses","False Claims Act and related","kickbacks and bribery","Opioid manufacturer Insys Therapeutics agreed to a global resolution to settle federal criminal and civil investigations regarding its sale of the powerful opioid Subsys. As part of the criminal resolution, Insys entered into a deferred prosecution agreement, pled guility to five counts of mail fraud, and paid a $2 million fine and $28 million in forfeiture. As part of the civil resolution, Insys agreed to pay $195 million to settle allegations that it violated the False Claims Act. Both the criminal and civil investigations stemmed from Insys's payment of kickbacks and other unlawful marketing practices in connection with the marketing of Subsys. ","federal","agency action","Justice Department Civil Division","civil and criminal","deferred prosecution agreement","","","","","","","","","","","USA","Arizona","out of business","","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/opioid-manufacturer-insys-therapeutics-agrees-enter-225-million-global-resolution-criminal",""
"Insys","Insys Therapeutics","$1,100,000","$0","$1,100,000","2015","20150805","healthcare-related offenses","off-label or unapproved promotion of medical products","kickbacks and bribery","The Oregon Attorney General reached a $1.1 million settlement with Insys, manufacturer of the schedule II opioid drug Subsys, to resolve allegations that the powerful drug approved by the Food and Drug Administration to treat cancer pain was marketed in Oregon for off-label uses such as non-cancer neck and back pain. The company was also alleged to have given improper financial incentives to doctors.","state","agency action","Oregon Attorney General","civil","","","","","","Oregon","","","","","","USA","Arizona","out of business","","pharmaceuticals","pharmaceuticals","https://www.doj.state.or.us/media-home/news-media-releases/ag-rosenblum-settles-with-pharmaceutical-company-insys-over-unlawful-promotion-of-the-powerful-opioid-subsys/",""
"Insys Therapeutics Inc.","Insys Therapeutics","$4,450,000","$0","$4,450,000","2017","20170818","healthcare-related offenses","off-label or unapproved promotion of medical products","","Insys agreed to pay $4.45 million in settlement of allegations it deceptively promoted and sold its opioid painkiller for treatments not approved by the Food and Drug Administration.","state","agency action","Illinois Attorney General","civil","","","","","","Illinois","","","","","","USA","Arizona","out of business","","pharmaceuticals","pharmaceuticals","https://web.archive.org/web/20170926234858/http://www.illinoisattorneygeneral.gov/pressroom/2017_08/20170818.html",""
"Insys Therapeutics, Inc.","Insys Therapeutics","$500,000","$0","$500,000","2017","20171003","healthcare-related offenses","off-label or unapproved promotion of medical products","kickbacks and bribery","Insys Therapeutics, Inc. agreed to pay $500,000 in settlement of allegations it unlawfully marketed its Fentanyl spray and paid kickbacks to persuade providers to prescribe the product.","state","agency action","Massachusetts Attorney General","civil","","","","","","Massachusetts","","","","","","USA","Arizona","out of business","","pharmaceuticals","pharmaceuticals","https://wayback.archive-it.org/1101/20181226231520/https://www.mass.gov/news/ag-healey-reaches-agreement-with-opioid-maker-over-widespread-marketing-scheme-to-increase",""
